Literature DB >> 18824610

Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.

Diego A Goyeneche-Patino1, Liliana Valderrama, John Walker, Nancy G Saravia.   

Abstract

The participation of trypanothione in clinical and experimental antimony (Sb) resistance in Leishmania panamensis was examined by using specific inhibitors. Buthionine sulfoximine (BSO) significantly reversed the resistance to trivalent Sb (Sb(III)) of promastigotes of experimentally derived Sb-resistant lines, supporting the participation of a trypanothione-mediated mechanism of resistance. In contrast, promastigotes of strains isolated at the time of clinical treatment failure and resistant to pentavalent Sb (Sb(V)) as intracellular amastigotes were not cross resistant to Sb(III), and BSO had little or no effect on susceptibility. Difluoromethylornithine did not alter the Sb(III) susceptibilities of experimentally selected lines or clinical strains. The mechanisms of acquired resistance emerging in clinical settings may differ from those selected by in vitro exposure to Sb.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18824610      PMCID： PMC2592887          DOI： 10.1128/AAC.01075-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.

Authors:  Helen Denton; Joanne C McGregor; Graham H Coombs
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

2.  Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

Authors:  J D Chulay; L Fleckenstein; D H Smith
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

3.  Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae.

Authors:  K Grondin; A Haimeur; R Mukhopadhyay; B P Rosen; M Ouellette
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

4.  Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania.

Authors:  R Mukhopadhyay; S Dey; N Xu; D Gage; J Lightbody; M Ouellette; B P Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites.

Authors:  Christian Brochu; Jingyu Wang; Gaétan Roy; Nadine Messier; Xiao-Yan Wang; Nancy G Saravia; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.

Authors:  W L Roberts; J D Berman; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam.

Authors:  Yao Zhou; Nadine Messier; Marc Ouellette; Barry P Rosen; Rita Mukhopadhyay
Journal:  J Biol Chem       Date:  2004-06-25       Impact factor: 5.157

Review 8.  Metabolism and functions of trypanothione in the Kinetoplastida.

Authors:  A H Fairlamb; A Cerami
Journal:  Annu Rev Microbiol       Date:  1992       Impact factor: 15.500

9.  Drug cytotoxicity assay for African trypanosomes and Leishmania species.

Authors:  A L Bodley; M W McGarry; T A Shapiro
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

10.  Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.

Authors:  D Sereno; M Cavaleyra; K Zemzoumi; S Maquaire; A Ouaissi; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191
View more
  16 in total

1.  Drug search for leishmaniasis: a virtual screening approach by grid computing.

Authors:  Rodrigo Ochoa; Stanley J Watowich; Andrés Flórez; Carol V Mesa; Sara M Robledo; Carlos Muskus
Journal:  J Comput Aided Mol Des       Date:  2016-07-20       Impact factor: 3.686

2.  Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.

Authors:  Tatiana R de Moura; Micheli Luize Barbosa Santos; Juciene M Braz; Luis Felipe V C Santos; Matheus T Aragão; Fabricia A de Oliveira; Priscila L Santos; Ângela Maria da Silva; Amélia Ribeiro de Jesus; Roque P de Almeida
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

3.  Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Authors:  Maria Claudia Barrera; Laura Jimena Rojas; Austin Weiss; Olga Fernandez; Diane McMahon-Pratt; Nancy G Saravia; Maria Adelaida Gomez
Journal:  Acta Trop       Date:  2017-08-24       Impact factor: 3.112

4.  Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Authors:  Arpita Kulshrestha; Vanila Sharma; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2014-01-22       Impact factor: 2.289

Review 5.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

6.  Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.

Authors:  Olga Fernández; Yira Diaz-Toro; Liliana Valderrama; Clemencia Ovalle; Mabel Valderrama; Harry Castillo; Mauricio Perez; Nancy Gore Saravia
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

7.  Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.

Authors:  Kelly C Kato; Eliane Morais-Teixeira; Priscila G Reis; Neila M Silva-Barcellos; Pascal Salaün; Paula P Campos; José Dias Corrêa-Junior; Ana Rabello; Cynthia Demicheli; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

8.  Antimony resistance in leishmania, focusing on experimental research.

Authors:  Fakhri Jeddi; Renaud Piarroux; Charles Mary
Journal:  J Trop Med       Date:  2011-11-17

9.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.

Authors:  Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

10.  Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum.

Authors:  Philippe Leprohon; Danielle Légaré; Frédéric Raymond; Eric Madore; Gary Hardiman; Jacques Corbeil; Marc Ouellette
Journal:  Nucleic Acids Res       Date:  2009-01-07       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.